Proton Pencil Beam Scanning Facilitates the Safe Treatment of Extended Radiation Targets for Hodgkin Lymphoma: A Report from the Proton Collaborative Group Registry.

extended target radiation therapy pencil beam scanning proton beam therapy

Journal

Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829

Informations de publication

Date de publication:
01 Aug 2024
Historique:
received: 29 06 2024
revised: 28 07 2024
accepted: 29 07 2024
medline: 10 8 2024
pubmed: 10 8 2024
entrez: 10 8 2024
Statut: epublish

Résumé

Because proton beam therapy (PBT) can lower the dose of radiation to the heart, lungs, and breast, it is an established radiation modality for patients with Hodgkin lymphoma (HL). Pencil beam scanning (PBS) PBT facilitates the treatment of more extensive targets. This may be especially of value for lymphoma patients who require RT to both mediastinal and axillary targets, defined here as extended target RT (ETRT), given the target distribution and need to minimize the lung, heart, and breast dose. Using the Proton Collaborative Group registry, we identified patients with HL treated with PBT to both their mediastinum and axilla, for which DICOM-RT was available. All patients were treated with PBS. To evaluate the dosimetric impact of PBS, we compared delivered PBS plans with VMAT butterfly photon plans optimized to have the same target volume coverage, when feasible. Between 2016 and 2021, twelve patients (median 26 years) received PBS ETRT (median 30.6 Gy (RBE)). Despite the large superior/inferior (SI, median 22.2 cm) and left/right (LR, median 22.8 cm) extent of the ETRT targets, all patients were treated with one isocenter except for two patients (both with SI and LR > 30 cm). Most commonly, anterior beams, with or without posterior beams, were used. Compared to photons, PBS had greater target coverage, better conformity, and lower dose heterogeneity while achieving lower doses to the lungs and heart, but not to the breast. No acute grade 3+ toxicities were reported, including pneumonitis. Proton ETRT in this small cohort was safely delivered with PBS and was associated with an improved sparing of the heart and lungs compared to VMAT.

Identifiants

pubmed: 39123464
pii: cancers16152736
doi: 10.3390/cancers16152736
pii:
doi:

Types de publication

Journal Article

Langues

eng

Auteurs

Maryam Ebadi (M)

Department of Radiation Oncology, University of Washington and Radiation Oncology Division, Fred Hutch Cancer Center, Seattle, WA 98195, USA.

Mark Pankuch (M)

Northwestern Medicine Proton Center, Warrenville, IL 60555, USA.

Sean Boyer (S)

Northwestern Medicine Proton Center, Warrenville, IL 60555, USA.

John Chang (J)

The Oklahoma Proton Center, Oklahoma City, OK 73142, USA.

Craig Stevens (C)

Department of Radiation Oncology, Corewell Health William Beaumont University Hospital, Royal Oak, MI 48073, USA.

Matthew D Hall (MD)

Miami Cancer Institute, Baptist Health South Florida, Miami, FL 33176, USA.

Shaakir Hasan (S)

New York Proton Center, New York, NY 10035, USA.

James E Bates (JE)

Emory University Hospital Midtown, Atlanta, GA 30308, USA.

Stella Flampouri (S)

Emory School of Medicine, Atlanta, GA 30322, USA.

Adam J Kole (AJ)

Department of Radiation Oncology, University of Alabama at Birmingham, Birmingham, AL 35294, USA.

Pranshu Mohindra (P)

University Hospitals Seidman Cancer Center, Cleveland, OH 44106, USA.

Carl Rossi (C)

California Protons Cancer Therapy Center, San Diego, CA 92121, USA.

Parag Sanghvi (P)

Department of Radiation Medicine and Applied Sciences, UC San Diego School of Medicine, La Jolla, CA 92093, USA.

Lisa McGee (L)

Department of Radiation Oncology, Mayo Clinic, Phoenix, AZ 85054, USA.

Zaker Rana (Z)

Maryland Proton Treatment Center, Baltimore, MD 21201, USA.

Yolanda D Tseng (YD)

Department of Radiation Oncology, University of Washington and Radiation Oncology Division, Fred Hutch Cancer Center, Seattle, WA 98195, USA.

Classifications MeSH